ADMET and DMPK, Vol. 4 No. 3, 2016.

Sadržaj

Puni tekst

ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors (str. 182-185)

Godefridus Peters, Kin Tam
Uvodnik

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer (str. 186-211)

Jonathan R. Thompson, Smitha P. Menon, Grace K. Dy
Pregledni rad

Cardiovascular safety of protein kinase inhibitors: putting their “QT-phobia” in perspective (str. 212-231)

Rashmi Shah
Pregledni rad

Cross talk of c-Jun N-terminal kinase and p38 map kinase modulate insulin and TNFα-stimulated VCAM-1 expression in rat aorta endothelial cells (str. 232-240)

Gregory B. Pott, Mark Tsurudome, Jamie Bui, Chelsea Gardner, Marc Goalstone
Izvorni znanstveni članak

Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria (str. 241-260)

Vishnu D Sharma, Aman Singla, Manu Chaudhary, Mukesh Kumar, Anuj Bhatnagar, Shailesh Kumar, Manish Taneja
Izvorni znanstveni članak

Evaluation of P-glycoprotein expression in pain relevant tissues: understanding translation of efflux from preclinical species to human (str. 261-268)

Renu Singh Dhanikula, Cyrla Hoffert, Rebecca Grant, Denis Projean, Rosemarie Panetta, Dajan O’Donnell, Marie Roumi
Izvorni znanstveni članak

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters (str. 269-279)

Thirumaleswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad
Izvorni znanstveni članak

Posjeta: 10.450 *